Intelligent Fingerprinting has expanded its presence in the Asia Pacific region with the appointment of Seoul-based Unimed Pharm Inc. as the official distributor for our fingerprint drug testing solution in South Korea.
Founded in 1991, Unimed has continued to develop its business in the pharmaceutical and healthcare markets – researching, developing, manufacturing and marketing a broad range of diagnostic, therapeutic and OTC products under strict compliance with South Korea’s GMP and QC procedures.
Commenting on the addition of fingerprint-based drug testing to its portfolio of solutions, Unimed’s CEO, Kim Keun-Nam said: “our plan is to replace the traditional urine-based tests we currently offer with the Intelligent Fingerprinting solution. Both Unimed and our customers expect the fingerprint-based test to deliver real benefits in terms of more dignified and hygienic testing, and we also expect the new solution to prove more efficient as it doesn’t require specialist collection and sample processing facilities. We believe that the Intelligent Fingerprinting approach, thanks to its innovative design, will prove an exciting proposition for Unimed.
“Our initial focus will be on the criminal justice, workplace and drug rehabilitation markets, and we think that Intelligent Fingerprinting’s innovative approach will provide a great differentiator for Unimed. We look forward to a successful partnership,” he continued.
Dr Paul Yates of Intelligent Fingerprinting added: “Unimed promotes innovative products to some of our key existing target markets. With their medical device experience and strong footprint we believe Unimed will prove the right partner to introduce Intelligent Fingerprinting to the South Korean marketplace.”
Unimed has headquarters in Seoul, with further Korean operations in the cities of Asan and Osong where it manufactures and exports finished products, API, cosmetic products, health foods and medical devices.
UNIMED PHARM INC.
UNIMED Building. 69, Samjeon-ro,
Songpa-Gu, Seoul, Korea